Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $500

10/19/2026
Impact: 80
Healthcare

Canaccord Genuity analyst Kyle Mikson has maintained a 'Buy' rating on Natera (NASDAQ: NTRA) and increased the price target from $375 to $500. This adjustment reflects a positive outlook for the company's performance.

AI summary, not financial advice

Share: